Dr Kellie Charles

Senior Lecturer
Pharmacology, School of Medical Sciences
Bosch Institute

Telephone +61 2 9036 5239

Map

Research interests

Dr Charles' research aims to investigate the interactions between malignant cells and immune cells that regulate tumour progression.Malignant cells secrete cytokines and chemokines that alter the phenotype and behaviour of tumour-associated leucocytes to promote tumour growth and orchestrate the immunosuppressant behaviour of the adaptive immune responses. Inhibiting the communication between cancer cells and immune cells is becoming an exciting potential target for cancer intervention strategies. Dr Charles conducts translational and clinical studies aimed to identify new molecular targets in cancer and in collaboration with biological chemists at the University of Sydney design and evaluate new cancer therapeutic agents.

International links

United Kingdom

(Centre of Cancer and Inflammation Institute of Cancer and CRUK Clinical School School of Medicine and Dentistry Queen Mary, University of London and Barts London, UK, EC1M6BQ) Collaboration with Prof Frances Balkwill and Dr Thorsten Hagemann

Selected grants

2013

  • A high-throughput, bright-field and fluorescence digital slide scanning platform and service that is both research and teaching-focused and available University-wide.; King N, Graeber M, Naylor M, Slapeta J, Quinnell R, Charles (nee Slaviero) K, Owens T, Bourne R, Braet F, Hambly B, Overall R, Stone J, Twigg S, Hardikar A, Halliday G, Richardson D, Byrne M, Keay K, Marsh D, Howell V, Pollock C, Chen X; DVC Research/Equipment Grant.
  • Robotic High Throughput Western Analysis for the Open Access, Multi-User Sydney Cancer Research Core Facility; Richardson D, Scolyer R, Boyer M, Halliday G, Damian D, Christopherson R, Joshua D, Kench J, Hong A, Murray M, Lee C, Kalinowski D, Naylor M, Lay P, Lyons G, Kovacevic Z, Mason R, Dixon K, Chan-Ling T, Hawkins C, Sunde M, Lovejoy D, Owens T, Rendina L, Jansson P, Dos Remedios C, Charles (nee Slaviero) K, Lane D, Witting P, Dong Q, Ammit A, Groundwater P, Assinder S, Bao B, Byrne S, Zhou F, Buckland M, Grewal T, Huq F, Lai D, Codd R, Zhang D, Fu D, de Graaf S, Huang M, Payne R, Slobedman B, Barrs V, Ho J, Williamson P, Murphy C; DVC Research/Equipment Grant.

2011

  • INFLAMMATORY BIOMARKERS OF CHEMOTHERAPY RESPONSE IN COLORECTAL CANCER; Charles (nee Slaviero) K; Cancer Institute New South Wales/Career Development Fellowship.

2010

  • A proteomic approach to identify predictive biomarkers of molecular targeted drugs; Charles (nee Slaviero) K, Clarke S; Cancer Institute New South Wales/Research Innovation Grants.

2009

  • Identification of potential drug targets in human colorectal tumours; Charles (nee Slaviero) K; University of Sydney/Early Career Researcher.
  • Targeting myeloid cells to restore anti-tumour responses in cancer.; Charles (nee Slaviero) K; Clive & Vera Ramaciotti Foundation/Awards for Biomedical Research: Establishment Gifts.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Elens, L., Nieuweboer, A., Clarke, S., Charles (nee Slaviero), K., De Graan, A., Haufroid, V., Mathijssen, R., Van Schaik, R. (2013). CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics, 14(2), 137-149. [More Information]
  • Elens, L., Nieuweboer, A., Clarke, S., Charles (nee Slaviero), K., De Graan, A., Haufroid, V., van Gelder, T., Mathijssen, R., Van Schaik, R. (2013). Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenetics and Genomics, 23(3), 148-155. [More Information]
  • Guthrie, G., Charles (nee Slaviero), K., Roxburgh, C., Horgan, P., McMillan, D., Clarke, S. (2013). The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Critical Reviews in Oncology / Hematology (online), 88(1), 218-230. [More Information]
  • Chua, W., Clarke, S., Charles (nee Slaviero), K. (2012). Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Supportive Care in Cancer, 20(8), 1869-1874. [More Information]
  • Chua, W., Kho, P., Moore, M., Charles (nee Slaviero), K., Clarke, S. (2011). Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Critical Reviews in Oncology / Hematology, 79(3), 224-250. [More Information]
  • Chua, W., Charles (nee Slaviero), K., Baracos, V., Clarke, S. (2011). Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. British Journal of Cancer, 104(8), 1288-1295. [More Information]
  • Clarke, S., Chua, W., Moore, M., Kao, S., Phan, V., Tan, C., Charles (nee Slaviero), K., McMillan, D. (2011). Use of inflammatory markers to guide cancer treatment. Clinical Pharmacology and Therapeutics, 90(3), 475-478. [More Information]
  • Moore, M., Chua, W., Charles (nee Slaviero), K., Clarke, S. (2010). Inflammation and Cancer: Causes and Consequences. Clinical Pharmacology and Therapeutics, 87(4), 504-508. [More Information]
  • Chua, W., Moore, M., Charles (nee Slaviero), K., Clarke, S. (2009). Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. Current Opinion in Molecular Therapeutics, 11(6), 611-622. [More Information]
  • Charles (nee Slaviero), K., Kulbe, H., Soper, R., Escorcio-Correia, M., Lawrence, T., Schultheis, A., Chakravarty, P., Thomson, R., Kollias, G., Smyth, J., et al (2009). The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans. Journal of Clinical Investigation, 119(10), 3011-2023. [More Information]
  • Hagemann, T., Lawrence, T., McNeish, I., Charles (nee Slaviero), K., Kulbe, H., Thompson, R., Robinson, S., Balkwill, F. (2008). "Re-educating" tumor-associated macrophages by targeting NF-κB. The Journal of Experimental Medicine, 205(6), 1261-1268. [More Information]
  • Brown, E., Charles (nee Slaviero), K., Hoare, S., Rye, R., Jodrell, D., Aird, R., Vora, R., Prabhakar, U., Nakada, M., Corringham, R., et al (2008). A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Annals of Oncology, 19(7), 1340-1346. [More Information]
  • Hagemann, T., Robinson, S., Thompson, R., Charles (nee Slaviero), K., Kulbe, H., Balkwill, F. (2007). Ovarian cancer cell–derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Molecular Cancer Therapeutics, 6(7), 1993-2002. [More Information]
  • Harrison, M., Obermueller, E., Maisey, N., Hoare, S., Edmonds, K., Li, N., Chao, D., Hall, K., Lee, C., Timotheadou, E., Charles (nee Slaviero), K., et al (2007). Tumor necrosis Factor α as a new target for renal cell carcinoma: Two sequential phase II trials of infliximab at standard and high dose. Journal of Clinical Oncology, 25(29), 4542-4549. [More Information]
  • Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li, N., Plüddemann, A., Charles (nee Slaviero), K., Gordon, S., Balkwill, F. (2006). Ovarian Cancer Cells Polarize Macrophages Toward A Tumor-Associated Phenotype. Journal of Immunology, 176(8), 5023-5032. [More Information]
  • Charles (nee Slaviero), K., Rivory, L., Stockler, M., Beale, P., Beith, J., Boyer, M., Clarke, S. (2006). Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical Pharmacokinetics, 45(6), 611-622. [More Information]
  • Charles (nee Slaviero), K., Rivory, L., Brown, S., Liddle, C., Clarke, S., Robertson, G. (2006). Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clinical Cancer Research, 12(24), 7492-7497. [More Information]
  • Szlosarek, P., Charles (nee Slaviero), K., Balkwill, F. (2006). Tumour necrosis factor-alpha as a tumour promoter. European Journal of Cancer, 42(6), 745-750. [More Information]
  • Hagemann, T., Wilson, J., Kulbe, H., Li, N., Leinster, D., Charles (nee Slaviero), K., Klemm, F., Pukrop, T., Binder, C., Balkwill, F. (2005). Macrophages Induce Invasiveness of Epithelial Cancer Cells Via NF-κB and JNK. Journal of Immunology, 175(2), 1197-1205. [More Information]
  • Balkwill, F., Charles (nee Slaviero), K., Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 7(3, March 2005), 211-217. [More Information]
  • Charles (nee Slaviero), K., Clarke, S., McLachlan, A., Blair, E., Rivory, L. (2004). Population Pharmacokinetics Of Weekly Docetaxel In Patients With Advanced Cancer. British Journal of Clinical Pharmacology, 57(1), 44-53.
  • Charles (nee Slaviero), K., Read, J., Clarke, S., Rivory, L. (2003). Baseline Nutritional Assessment in Advanced Cancer Patients Receiving Palliative Chemotherapy. Nutrition and Cancer: an international journal, 46(2), 148-157.
  • Charles (nee Slaviero), K., Clarke, S., Rivory, L. (2003). Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncology, 4(4), 224-232.
  • Rivory, L., Charles (nee Slaviero), K., Clarke, S. (2002). Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. British Journal of Cancer, 87(3), 277-280.
  • Rivory, L., Charles (nee Slaviero), K., Hoskins, J., Clarke, S. (2001). The erythromycin breath test for the prediction of drug clearance. Clinical Pharmacokinetics, 40, 151-158.
  • Rivory, L., Charles (nee Slaviero), K., Seale, J., Hoskins, J., Boyer, M., Beale, P., Millward, M., Bishop, J., Clarke, S. (2000). Optimizing the erythromycin breath test for use in cancer patients. Clinical Cancer Research, 6, 3480-3485.

2013

  • Elens, L., Nieuweboer, A., Clarke, S., Charles (nee Slaviero), K., De Graan, A., Haufroid, V., Mathijssen, R., Van Schaik, R. (2013). CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics, 14(2), 137-149. [More Information]
  • Elens, L., Nieuweboer, A., Clarke, S., Charles (nee Slaviero), K., De Graan, A., Haufroid, V., van Gelder, T., Mathijssen, R., Van Schaik, R. (2013). Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenetics and Genomics, 23(3), 148-155. [More Information]
  • Guthrie, G., Charles (nee Slaviero), K., Roxburgh, C., Horgan, P., McMillan, D., Clarke, S. (2013). The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Critical Reviews in Oncology / Hematology (online), 88(1), 218-230. [More Information]

2012

  • Chua, W., Clarke, S., Charles (nee Slaviero), K. (2012). Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Supportive Care in Cancer, 20(8), 1869-1874. [More Information]

2011

  • Chua, W., Kho, P., Moore, M., Charles (nee Slaviero), K., Clarke, S. (2011). Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Critical Reviews in Oncology / Hematology, 79(3), 224-250. [More Information]
  • Chua, W., Charles (nee Slaviero), K., Baracos, V., Clarke, S. (2011). Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. British Journal of Cancer, 104(8), 1288-1295. [More Information]
  • Clarke, S., Chua, W., Moore, M., Kao, S., Phan, V., Tan, C., Charles (nee Slaviero), K., McMillan, D. (2011). Use of inflammatory markers to guide cancer treatment. Clinical Pharmacology and Therapeutics, 90(3), 475-478. [More Information]

2010

  • Moore, M., Chua, W., Charles (nee Slaviero), K., Clarke, S. (2010). Inflammation and Cancer: Causes and Consequences. Clinical Pharmacology and Therapeutics, 87(4), 504-508. [More Information]

2009

  • Chua, W., Moore, M., Charles (nee Slaviero), K., Clarke, S. (2009). Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. Current Opinion in Molecular Therapeutics, 11(6), 611-622. [More Information]
  • Charles (nee Slaviero), K., Kulbe, H., Soper, R., Escorcio-Correia, M., Lawrence, T., Schultheis, A., Chakravarty, P., Thomson, R., Kollias, G., Smyth, J., et al (2009). The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans. Journal of Clinical Investigation, 119(10), 3011-2023. [More Information]

2008

  • Hagemann, T., Lawrence, T., McNeish, I., Charles (nee Slaviero), K., Kulbe, H., Thompson, R., Robinson, S., Balkwill, F. (2008). "Re-educating" tumor-associated macrophages by targeting NF-κB. The Journal of Experimental Medicine, 205(6), 1261-1268. [More Information]
  • Brown, E., Charles (nee Slaviero), K., Hoare, S., Rye, R., Jodrell, D., Aird, R., Vora, R., Prabhakar, U., Nakada, M., Corringham, R., et al (2008). A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Annals of Oncology, 19(7), 1340-1346. [More Information]

2007

  • Hagemann, T., Robinson, S., Thompson, R., Charles (nee Slaviero), K., Kulbe, H., Balkwill, F. (2007). Ovarian cancer cell–derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Molecular Cancer Therapeutics, 6(7), 1993-2002. [More Information]
  • Harrison, M., Obermueller, E., Maisey, N., Hoare, S., Edmonds, K., Li, N., Chao, D., Hall, K., Lee, C., Timotheadou, E., Charles (nee Slaviero), K., et al (2007). Tumor necrosis Factor α as a new target for renal cell carcinoma: Two sequential phase II trials of infliximab at standard and high dose. Journal of Clinical Oncology, 25(29), 4542-4549. [More Information]

2006

  • Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li, N., Plüddemann, A., Charles (nee Slaviero), K., Gordon, S., Balkwill, F. (2006). Ovarian Cancer Cells Polarize Macrophages Toward A Tumor-Associated Phenotype. Journal of Immunology, 176(8), 5023-5032. [More Information]
  • Charles (nee Slaviero), K., Rivory, L., Stockler, M., Beale, P., Beith, J., Boyer, M., Clarke, S. (2006). Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical Pharmacokinetics, 45(6), 611-622. [More Information]
  • Charles (nee Slaviero), K., Rivory, L., Brown, S., Liddle, C., Clarke, S., Robertson, G. (2006). Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clinical Cancer Research, 12(24), 7492-7497. [More Information]
  • Szlosarek, P., Charles (nee Slaviero), K., Balkwill, F. (2006). Tumour necrosis factor-alpha as a tumour promoter. European Journal of Cancer, 42(6), 745-750. [More Information]

2005

  • Hagemann, T., Wilson, J., Kulbe, H., Li, N., Leinster, D., Charles (nee Slaviero), K., Klemm, F., Pukrop, T., Binder, C., Balkwill, F. (2005). Macrophages Induce Invasiveness of Epithelial Cancer Cells Via NF-κB and JNK. Journal of Immunology, 175(2), 1197-1205. [More Information]
  • Balkwill, F., Charles (nee Slaviero), K., Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 7(3, March 2005), 211-217. [More Information]

2004

  • Charles (nee Slaviero), K., Clarke, S., McLachlan, A., Blair, E., Rivory, L. (2004). Population Pharmacokinetics Of Weekly Docetaxel In Patients With Advanced Cancer. British Journal of Clinical Pharmacology, 57(1), 44-53.

2003

  • Charles (nee Slaviero), K., Read, J., Clarke, S., Rivory, L. (2003). Baseline Nutritional Assessment in Advanced Cancer Patients Receiving Palliative Chemotherapy. Nutrition and Cancer: an international journal, 46(2), 148-157.
  • Charles (nee Slaviero), K., Clarke, S., Rivory, L. (2003). Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncology, 4(4), 224-232.

2002

  • Rivory, L., Charles (nee Slaviero), K., Clarke, S. (2002). Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. British Journal of Cancer, 87(3), 277-280.

2001

  • Rivory, L., Charles (nee Slaviero), K., Hoskins, J., Clarke, S. (2001). The erythromycin breath test for the prediction of drug clearance. Clinical Pharmacokinetics, 40, 151-158.

2000

  • Rivory, L., Charles (nee Slaviero), K., Seale, J., Hoskins, J., Boyer, M., Beale, P., Millward, M., Bishop, J., Clarke, S. (2000). Optimizing the erythromycin breath test for use in cancer patients. Clinical Cancer Research, 6, 3480-3485.

To update your profile click here. For support on your academic profile contact .